Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P060004/S011

MEL 90 Excimer Laser

Carl Zeiss Meditec, Inc. · Decision date Apr 30, 2026

FDA DECISIONP060004/S011

What did the FDA decide?

FDA records P060004/S011 as a supplement to PMA P060004, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 30, 2026.

FDA approval order statement

updates to the quality inspection process for the Fluence Test Cards
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Ophthalmic
Decision date
Apr 30, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P060004/S011
Regulatory pathway
PMA supplement
Product code
LZS
Decision code
OK30
Decision date
Apr 30, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Excimer laser system.

Product code
LZS
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P060004/S011 received

    Application receipt date recorded by FDA.

  2. P060004/S011 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P060004. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P060004

Product / regulatory recordCompanyPathwayDecision dateSource
Carl Zeiss Meditec, Inc.PMA supplementJul 1, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Carl Zeiss Meditec, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
5160 Hacienda Dr., Dublin, CA, 94568

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records